Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

Boehringer and Lilly close in on empagliflozin filing

But amend diabetes alliance after Boehringer drops basal insulin

- PMLiVE

Lilly delivers upbeat earnings forecast for 2013

New products will offset generic competition for Alimta, Zyprexa, Cymbalta and Evista

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

Lilly pays $29m to settle foreign bribery charges

US Securities and Exchange Commission charges centre on activities in Russia, China, Brazil and Poland

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Teva expands presence in South Korea with Handok deal

Will supply products for distribution in market worth $14bn

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Lilly stops tabalumab trial in arthritis on efficacy grounds

Will take a charge of around $20m to $35m

- PMLiVE

Lilly plans another trial for Alzheimer’s hope solanezumab

Presses on with another late-stage study for the drug

- PMLiVE

New UK managing director for Lilly

Dr Jean-Michel Cossery takes over from Ramona Sequeira

- PMLiVE

Lilly taps Strides Arcolab for cancer generics

Aims to expand its presence in emerging pharmaceutical markets

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links